Search results
Results from the WOW.Com Content Network
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]
Treatment of people aged twelve years of age and older with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy [2]
Elbasvir/grazoprevir, sold under the brand name Zepatier, is a fixed-dose combination for the treatment of hepatitis C, containing elbasvir (an inhibitor of hepatitis C virus's NS5A protein) and grazoprevir (an NS3/4A inhibitor). It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and ...
In fact, the rate of new hepatitis C cases more than quadrupled over the last decade, according to a study conducted by the Centers for Disease Control and Prevention (CDC). Dr. Dr.
Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. [3] It is taken by mouth. [3] [6]Common side effects include fatigue, headache, nausea, and trouble sleeping. [3]
Bristol-Myers Squibb's (NYS: BMY) latest data on its current hepatitis C drugs explain why the pharma needed to purchase Inihibitex (NAS: INHX) . A combination of its drugs -- daclatasvir and ...
Gilead Sciences has received FDA priority review status for its New Drug Application for sofosbuvir, the company announced Friday. Sofosbuvir is a once-daily oral nucleotide analogue inhibitor for ...
Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. [1] After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. [2] [3] The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication ...